Viatris Inc. (NASDAQ:VTRS) is one of the 13 extreme value stocks to buy now. Viatris Inc. (NASDAQ:VTRS) is covered by 12 analysts on Wall Street with a medium price target of $16, suggesting 12.36% ...

The memory-chip stock stands out when factoring in its inexpensive valuation, strong growth profile and sky-high margins Micron's stock trades at a forward price/earnings ratio of 5.6, which is one of ...

Viatris (VTRS) targets 5–6% revenue and 9–10% EPS CAGR through 2030, backed by launches, pipeline and $11B M&A cash. Click here to read my most recent analysis.

Viatris Inc. (Nasdaq: VTRS) will host its Investor Event today, where members of the executive leadership team will outline the Company's strategic vision, key drivers and financial framework expected ...

The Vanguard Small-Cap Value ETF (NYSEMKT:VBR) and iShares Morningstar Small-Cap Value ETF (NYSEMKT:ISCV) both target U.S. small-cap value stocks, but ISCV offers a marginally hig ...

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of ...

Growing Base Business Evolving Into More Durable Portfolio of Higher-Margin Generics, Value-Added Medicines and Established Brands Expecting Impactful Near-Term ...

Viatris (VTRS) stock is in focus as the company sets long-term targets: 5–6% revenue CAGR, 7–8% EBITDA, 9–10% EPS, plus $2.7B FCF through 2030. Read more here.

Viatris has already held an Investor Event where its leadership outlined the company’s long-term vision through 2030, including growth priorities, R&D focus, commercial strategy, portfolio management, ...

Theravance Biopharma TBPH reported fourth-quarter 2025 adjusted earnings of 6 cents per share, which missed the Zacks ...

This medical technology firm delivers integrated blood management solutions to healthcare providers and plasma centers ...